Royce & Associates LP boosted its position in shares of Definium Therapeutics, Inc. (NASDAQ:DFTX – Free Report) by 20.1% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 250,547 shares of the company’s stock after acquiring an additional 41,996 shares during the quarter. Royce & Associates LP’s holdings in Definium Therapeutics were worth $9,536,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wellington Management Group LLP purchased a new stake in Definium Therapeutics in the second quarter valued at approximately $138,755,000. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 116.1% in the third quarter. Russell Investments Group Ltd. now owns 331,702 shares of the company’s stock valued at $12,647,000 after acquiring an additional 178,225 shares during the period. Seven Fleet Capital Management LP purchased a new position in shares of Definium Therapeutics during the second quarter worth approximately $6,992,000. Moody Aldrich Partners LLC grew its position in shares of Definium Therapeutics by 191.8% during the third quarter. Moody Aldrich Partners LLC now owns 148,870 shares of the company’s stock worth $5,666,000 after acquiring an additional 97,845 shares during the last quarter. Finally, Lisanti Capital Growth LLC purchased a new position in shares of Definium Therapeutics during the third quarter worth approximately $2,647,000. Hedge funds and other institutional investors own 27.91% of the company’s stock.
Wall Street Analysts Forecast Growth
Several analysts recently commented on the stock. Wells Fargo & Company upped their price target on shares of Definium Therapeutics from $68.00 to $72.00 and gave the company an “overweight” rating in a research report on Thursday, August 13th. Maxim Group set a $55.00 price target on shares of Definium Therapeutics and gave the stock a “buy” rating in a research note on Friday, August 14th. Bank of America assumed coverage on shares of Definium Therapeutics in a research report on Tuesday, August 18th. They set a “buy” rating and a $75.00 price objective on the stock. Robert W. Baird lifted their price objective on shares of Definium Therapeutics from $75.00 to $79.00 and gave the company an “outperform” rating in a research note on Tuesday, September 15th. Finally, JonesTrading upped their target price on shares of Definium Therapeutics from $74.00 to $90.00 and gave the company a “buy” rating in a report on Thursday, August 13th. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $66.29.
Get Our Latest Research Report on DFTX
Insider Activity
In other news, insider Mark Sullivan sold 14,051 shares of the firm’s stock in a transaction on Friday, September 25th. The shares were sold at an average price of $36.57, for a total value of $513,845.07. Following the completion of the sale, the insider owned 494,228 shares in the company, valued at approximately $18,073,917.96. This trade represents a 2.76% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Matthew T. Wiley sold 3,097 shares of the firm’s stock in a transaction on Friday, September 25th. The stock was sold at an average price of $36.57, for a total transaction of $113,257.29. Following the completion of the sale, the insider owned 359,036 shares of the company’s stock, valued at $13,129,946.52. This trade represents a 0.86% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 71,098 shares of company stock valued at $2,626,115. 2.40% of the stock is owned by corporate insiders.
Definium Therapeutics Trading Down 2.6%
Shares of DFTX stock opened at $29.38 on Wednesday. The business’s 50 day moving average is $35.74 and its two-hundred day moving average is $30.51. Definium Therapeutics, Inc. has a twelve month low of $10.46 and a twelve month high of $49.70. The company has a market capitalization of $4.02 billion, a P/E ratio of -9.45 and a beta of 2.23. The company has a current ratio of 15.53, a quick ratio of 15.53 and a debt-to-equity ratio of 0.04.
Definium Therapeutics (NASDAQ:DFTX – Get Free Report) last released its quarterly earnings results on Monday, November 9th. The company reported ($0.46) EPS for the quarter, topping the consensus estimate of ($0.55) by $0.09. Equities analysts forecast that Definium Therapeutics, Inc. will post -2.94 EPS for the current year.
Definium Therapeutics Company Profile
Definium Therapeutics, Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026.
Read More
- Five stocks we like better than Definium Therapeutics
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Want to see what other hedge funds are holding DFTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Definium Therapeutics, Inc. (NASDAQ:DFTX – Free Report).
Receive News & Ratings for Definium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Definium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
